利培酮治疗抑郁症与神经症患者躯体化症状临床研究

Clinical studies of risperdone in somatization symptoms of patients with depression and neurosis

目的探讨利培酮治疗抑郁症与神经症患者躯体化症状的临床疗效。方法将37例有明显躯体化症状的抑郁症和神经症患者随机分为研究组和对照组,两组均进行抗抑郁及抗焦虑治疗的同时,研究组联合小剂量利培酮治疗,疗程6w。治疗前及治疗2w、4w、6w末采用症状自评量表进行临床疗效评定与分析。结果研究组治疗4w、6w末躯体化因子评分较治疗前均有显著下降,与对照组同期评分比较差异有显著或极显著性(P<0.05或0.01)。结论利培酮联合抗抑郁及抗焦虑药物治疗躯体化症状疗效较好。

Objective To explore the curative effects of risperdone in the treatment of somatization symptoms of patients with depression and neurosis. Methods 37 patients with depression and neurosis who had obvious somatization symptoms were randomly divided into research group（n=19） and control group（n= 18）, both 2 groups received antidepressants and antianxietic, meanwhile the research group combined with low dosed of risperdone for 6 weeks. Curative effects were assessed with the Symptom Checklist 90（SCL- 90） before treatment and at the ends of the 2nd, 4th and 6th week of treatment. Results At the ends of the 4th and 6th week, somatization factor score decreased significantly in the research group compared with pre-treatment and had significant and very difference from the control group（P〈0.05 or 0.01）. Conclusion Risperdone combined with antidepressants and antianxietic has better effectiveness in somatization symptoms.